~~<i id='5DD1FD35B6'><strike id='5DD1FD35B6'><tt id='5DD1FD35B6'><pre id='5DD1FD35B6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：explore 2025-08-21 08:26:54 - browse：261

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Obesity drugs seen as possible treatment for liver disease MASH

explore

knowledge

hotspot

entertainment

Wikipedia

AdobeDarioHealth,whichmakesappsformanagingchronicdiseases,todayannounceditwillacquiredigitalmentalhe

WSS

FTC sues over Novant Health acquisition of two N.C. hospitals

Syphilis numbers in the United States reach record heights

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Pancreatic cancer early detection could be helped by AI

Pancreatic cancer early detection could be helped by AI

Medicare drug price negotiation legal challenge met with skepticism

explore

entertainment

explore

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Malaria cases in Florida and Texas: Here’s what you need to know

Merck, Johnson & Johnson CEOs will testify on high drug prices

Cancer drug shortages should be causing more outrage

New clues to why women have higher risk of autoimmune disorders

knowledge

In utero gene editing: an explainer

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Reconstructing family trees of blood cells may help predict disease

Zyn nicotine pouches become unlikely player in latest culture war

Alabama frozen embryo ruling has major implications for IVF clinics

Biogen walks away from Aduhelm, years after polarizing approval

hotspot

hotspot

entertainment

Wikipedia